Technical Analysis for GLYC - GlycoMimetics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Calm After Storm | Range Contraction | 0.00% | |
Upper Bollinger Band Walk | Strength | 0.00% | |
Earnings Movers | Other | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Parabolic Rise | Strength | -5.97% | |
Upper Bollinger Band Walk | Strength | -5.97% | |
Wide Bands | Range Expansion | -5.97% | |
Upper Bollinger Band Touch | Strength | -5.97% |
Alert | Time |
---|---|
Down 5% | about 19 hours ago |
Possible Inside Day | about 19 hours ago |
60 Minute Opening Range Breakdown | about 20 hours ago |
Up 3% | about 23 hours ago |
Up 2% | about 23 hours ago |
Get a Trading Assistant
- Earnings date: 11/01/2024
GlycoMimetics, Inc. Description
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases. Its lead product includes GMI-1070, a glycomimetic drug candidate that acts as a pan-selectin antagonist has completed Phase II clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The company is also developing GMI-1271, a specific E-selectin antagonist, which it plans to initiate a Phase I dose-escalation clinical trials in healthy volunteers to be used in combination with chemotherapy to treat acute myeloid leukemia and potentially other hematologic cancers. In addition, its drug candidates comprise GMI-1051 and other drug candidates for pseudomonas virulence factors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Gaithersburg, Maryland.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Disease Drug Discovery Acute Myeloid Leukemia Chemotherapy Clinical Trial Product Testing Hematologic Cancers Pseudomonas Sickle Cell Disease Nursing Research
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.5299 |
52 Week Low | 0.1406 |
Average Volume | 24,390,377 |
200-Day Moving Average | 1.15 |
50-Day Moving Average | 0.19 |
20-Day Moving Average | 0.21 |
10-Day Moving Average | 0.28 |
Average True Range | 0.05 |
RSI (14) | 69.97 |
ADX | 39.58 |
+DI | 53.50 |
-DI | 8.11 |
Chandelier Exit (Long, 3 ATRs) | 0.47 |
Chandelier Exit (Short, 3 ATRs) | 0.30 |
Upper Bollinger Bands | 0.44 |
Lower Bollinger Band | -0.01 |
Percent B (%b) | 0.88 |
BandWidth | 209.64 |
MACD Line | 0.06 |
MACD Signal Line | 0.03 |
MACD Histogram | 0.0301 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.45 | ||||
Resistance 3 (R3) | 0.46 | 0.44 | 0.44 | ||
Resistance 2 (R2) | 0.44 | 0.42 | 0.44 | 0.44 | |
Resistance 1 (R1) | 0.41 | 0.41 | 0.40 | 0.41 | 0.43 |
Pivot Point | 0.39 | 0.39 | 0.39 | 0.39 | 0.39 |
Support 1 (S1) | 0.36 | 0.38 | 0.36 | 0.36 | 0.33 |
Support 2 (S2) | 0.35 | 0.36 | 0.34 | 0.33 | |
Support 3 (S3) | 0.32 | 0.35 | 0.33 | ||
Support 4 (S4) | 0.31 |